Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza mRNA-LNP vaccine (5xM2e)
- Development stage
- Preclinical
- Lead developer
- Georgia State University
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
influenza mRNA-LNP vaccine (5xM2e) is a preclinical mRNA-based vaccine candidate developed by Georgia State University. It consists of a lipid nanoparticle (LNP)-encapsulated messenger RNA (mRNA) encoding a tandem repeat of five conserved ectodomains of the matrix protein 2 (5xM2e) derived from human, swine, and avian influenza A viruses. The vaccine is designed to elicit broad, cross-protective immunity against diverse influenza A virus subtypes (such as H1, H3, and H5) by targeting the highly conserved M2e region. In preclinical studies, it has been shown to induce robust M2e-specific IgG antibodies, T-cell responses, and acute innate immune recruitment, and it can be co-administered with conventional seasonal split or protein-based influenza vaccines to significantly enhance their immunogenicity and protective efficacy.
- Other names
- 5xM2e mRNA LNP vaccine5xM2e mRNA lipid nanoparticle5xM2e mRNA lipid nanoparticle vaccine5xM2e mRNA vaccine5xM2e mRNA-LNP vaccine
02
Targets
CHRM2 (M2)
Beyond the preview
Go deeper on influenza mRNA-LNP vaccine (5xM2e).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza mRNA-LNP vaccine (5xM2e).